The fight against cardiovascular disease may have found a precision weapon in the form of genetically modified immune cells that specifically target the inflammatory drivers of arterial plaque buildup. This approach addresses a critical gap in current treatments, which primarily focus on lowering cholesterol levels but cannot selectively dampen the inflammatory cascade that transforms cholesterol into dangerous arterial deposits.
Researchers engineered regulatory T cells (Tregs) with chimeric antigen receptors designed to recognize oxidized low-density lipoprotein (OxLDL), a highly inflammatory molecule that accumulates in arterial walls and drives atherosclerotic plaque formation. These modified CAR Tregs demonstrated remarkable specificity, reducing macrophage foam cell formation—a key pathological process where immune cells become engorged with oxidized cholesterol and contribute to plaque instability. In mouse models of hyperlipidemia and atherosclerosis, the engineered cells successfully reduced plaque development through targeted immunosuppression.
This therapeutic strategy represents a paradigm shift from current cardiovascular interventions. Unlike statins or blood pressure medications that work systemically, CAR Tregs could theoretically provide site-specific anti-inflammatory action without broad immunosuppression. The approach borrows proven technology from cancer immunotherapy, where CAR T cells have shown remarkable success, and applies it to chronic inflammatory disease. However, significant hurdles remain before human application, including questions about long-term safety, optimal dosing, and whether the approach will translate effectively from mouse models to human atherosclerosis. The complexity of human plaque biology and potential autoimmune risks of targeting endogenous molecules like OxLDL will require extensive safety evaluation.